

Vol. 7, No. 1 7 January 1997

ISSN 0960-894X

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication
for Rapid Dissemination of
Preliminary Communications on all aspects of
Bioorganic Chemistry, Medicinal Chemistry,
Bioinorganic Chemistry and related disciplines

UW PHARMACY LIBRARY

Editor-in-Chief

DALE L BOGER

*The Scripps Research Institute
La Jolla*

*CA 92037
USA*



Chairman of the Executive
Board of Editors for
Tetrahedron Publications

SIR DEREK BARTON

*Texas A & M University
USA*



PERGAMON



European Regional Editor: **Professor L. Ghosez**, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
 Fax: (32) 10 47 29 44

Japanese Regional Editor: **Professor M. Shibasaki**, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
 Fax: (81) 3 5684 5206

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: Professor Sir Derek Barton, FRS, Department of Chemistry, Texas A & M University, College Station, Texas 77843-3255, USA

Professor J. E. Baldwin, FRS, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor S. G. Davies, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor A. R. Katritzky, FRS, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Professor N. K. Kochetkov, N. D. Zelinsky Institute of Organic Chemistry, Academy of Sciences, Moscow B-334, Russia

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Academia Sinica, Shanghai 200032, China

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor A. McKillop, University of East Anglia, School of Chemical Sciences, University Plain, Norwich, NR4 7TJ, UK

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor G. Ourisson, Centre National de la Recherche Scientifique, Centre de Neurochimie, 67084 Strasbourg, Cedex, France

(Associate Editor, Professor G. Solladié)

Professor G. H. Posner, Department of Chemistry, Johns Hopkins University, Baltimore, MD 21218, USA

Professor T. Shioiri, Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan

Professor W. Steglich, Institut für Organische Chemie der Universität München, Karlstr. 23, D-80333 München, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520-8107, USA
 (Associate Editor, Professor D. P. Curran)

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor Y. Yamamoto, Department of Chemistry, Faculty of Science, Tohoku University, Sendai 980-77, Japan
 (Associate Editor, Professor M. Hirama)

BOARD OF CONSULTING EDITORS

R. Abeles, Waltham, MA
 P. S. Anderson, Lansdale, PA
 J. K. Barton, Pasadena, CA
 S. J. Benkovic, Pennsylvania, PA
 R. C. Breslow, New York, NY
 J. A. Bristol, Ann Arbor, MI
 T. C. Bruice, Santa Barbara, CA
 A. R. Chamberlin, Irvine, CA
 J. P. Collman, Stanford, CA
 P. N. Confolone, Wilmington, DE
 E. J. Corey, Cambridge, MA
 S. J. Danishefsky, New York, NY
 P. B. Dervan, Pasadena, CA
 A. Eschenmoser, Zürich
 J.-M. Fang, Taipei
 A. R. Fersht, Cambridge

D. M. Floyd, Princeton, NJ
 A. K. Ganguly, Bloomfield, NJ
 D. Gani, St Andrews
 B. Giese, Basel
 H. B. Gray, Pasadena, CA
 J. T. Groves, Princeton, NJ
 G. L. Grunewald, Lawrence, KS
 P. Herrling, Basel
 D. Hilvert, La Jolla, CA
 R. H. Holm, Cambridge, MA
 D. C. Horwell, Cambridge
 B. Imperiali, Pasadena, CA
 K. Janda, La Jolla, CA
 W. L. Jorgensen, New Haven, CT
 D. D. Keith, Nutley, NJ
 P. Krosggaard-Larsen, Copenhagen

R. A. Lerner, La Jolla, CA
 S. J. Lippard, Cambridge, MA
 D. Mansuy, Paris
 B. W. Metcalf, King of Prussia, PA
 L. A. Mitscher, Lawrence, KS
 W. H. Moos, Emeryville, CA
 K. Mori, Tokyo
 K. Nakanishi, New York, NY
 K. C. Nicolaou, La Jolla, CA
 T. Ogawa, Saitama
 M. Ohno, Tokyo
 H. L. Pearce, Indianapolis, IN
 P. Potier, Gif-sur-Yvette
 C. D. Poulter, Salt Lake City, UT
 J. Rebek, Jr, Cambridge, MA

B. Samuelsson, Stockholm
 R. L. Schowen, Lawrence, KS
 S. L. Schreiber, Cambridge, MA
 P. G. Schultz, Berkeley, CA
 A. I. Scott, College Station, TX
 I. Shinkai, Rahway, NJ
 C. J. Sih, Madison, WI
 J. Stubbe, Cambridge, MA
 N. K. Terrett, Sandwich
 G. L. Verdine, Cambridge, MA
 H. Waldmann, Karlsruhe
 C. T. Walsh, Boston, MA
 G. Whitesides, Cambridge, MA
 R. V. Wolfenden, Chapel Hill, NC

PUBLISHED TWICE MONTHLY

Subscription Rates

Annual Institutional Subscription Rates 1997: Europe, The CIS and Japan 2210.00 NLG. All other countries US\$1364.00. NLG prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice. Any enquiry relating to subscriptions should be sent to:
The Americas: Elsevier Science, Customer Support Department, PO Box 945, New York, NY 10010, USA [Tel: (+1) 212-633-3730/1-888 4ES-INFO. Fax: (+1) 212-633-3680. E-mail: usinfo-f@elsevier.com].
Japan: Elsevier Science, Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan [Tel: (+81) 3-5561-5033. Fax: (+81) 3-5561-5047. E-mail: kyf04035@niftyserve.or.jp].
Asia Pacific (excluding Japan): Elsevier Science (Singapore) Pte Ltd, No. 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192. [Tel: (+65) 434-3727. Fax: (+65) 337-2230. E-mail: asiainfo@elsevier.com.sg].
Rest of the World: Elsevier Science Customer Service Department, PO Box 211, 1001 AE Amsterdam, The Netherlands [Tel: (+31) 20-485-3757. Fax: (+31) 20-485-3432. E-mail: nlinfo-f@elsevier.nl].

Copyright © 1996 Elsevier Science Ltd

D. L. Musco, N. B. Mehta and
F. E. Soroko

J. Campos Rosa,
B. M. Beckwith-Hall, D. Galanakis,
C. R. Ganellin, P. M. Dunn and
D. H. Jenkinson

D. P. Czajkowski, A. V. N. Reddy,
E. L. Setti, O. A. Phillips,
R. G. Micetich, C. Kunugita and
S. N. Maiti

T. Arai, K. Shinozuka and H. Sawai

B. R. Cunningham, M. Rivetna,
R. L. Toiman, S. J. Flattery,
E. A. Nichols, C. D. Schwartz,
L. S. Wicker, J. D. Hermes and
A. B. Jones

D. O. Calligaro, J. Fairhurst,
T. M. Hotten, N. A. Moore and
D. E. Tupper

D. C. Horwell, D. Naylor and
H. M. G. Willems

E. J. Schwartz, J. Goldberg,
C. Clayberger, A. M. Krensky and
J. H. Griffin

T. L. Graybill, C. P. Prouty,
G. J. Speier, D. Hoyer, R. E. Dolle,
C. T. Helaszek, M. A. Ator, J. Uhl
and J. Strasters

M. Thérien, C. Brideau, C. C. Chan,
W. A. Cromlish, J. Y. Gauthier,
R. Gordon, G. Greig, S. Kargman,
C. K. Lau, Y. Leblanc, C.-S. Li,
G. P. O'Neill, D. Riendeau, P. Roy,
Z. Wang, L. Xu and P. Prasit

iii Tetrahedron Prize for Creativity in Organic Chemistry

v Contributors to this Issue

vii Graphical Abstracts

1 Synthesis and evaluation of the anticonvulsant activity of a series of 2-amino-1-phenyl-1-propanols derived from the metabolites of the antidepressant bupropion

7 Bis-quinolinium cyclophanes: a novel class of potent blockers of the apamin-sensitive Ca^{2+} -activated K^+ channel

11 Studies on penam sulfones—III. Synthesis and β -lactamase inhibitory activity of sodium (6*R*)-6-(α -hydroxybenzyl)-2 β -methoxyiminomethyl-2 α -methylpenam-3 α -carboxylate 1,1-dioxide and sodium 2 β -acyl-2 α -methylpenam-3 α -carboxylate 1,1-dioxide

15 Bleomycin model complex bearing a carbamoyl derived substituent capable of coordination to the chelated metal ion as a sixth ligand

19 SAR for MHC class II binding tetrapeptides: correlation with potential binding site

25 The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)

31 2,3-Substituted 2-azanorbornanes as polar β -turn mimetics

37 Structure-activity studies of CTL inhibitory peptides derived from HLA class I molecules

41 α -((Tetronoyl)oxy)- and α -((tetramoyl)oxy)methyl ketone inhibitors of the interleukin-1 β converting enzyme (ICE)

47 Synthesis and biological evaluation of 5,6-diarylimidazo[2,1-*b*]thiazole as selective COX-2 inhibitors

[Continued on inside back cover]



0960-894X(1997)7:1;1-I

TW PHARMACY LIBRARY

Indexed/Abstracted in: Chemical Abstracts, Current Contents,
Science Citation Index, SciSearch, Research Alert, Excerpta Medica
Database EMBASE, CABS (Current Awareness in Biological Sciences)

BMCLE8 7 (1) 1-98 (1997)



Pergamon

Printed in Great Britain by Nuffield Press Ltd.

972

Contents [Continued from outside back cover]

- L. A. Trimble, N. Chauret,
J. M. Silva, D. A. Nicoll-Griffith,
C.-S. Li and J. A. Yergey 53 Characterization of the *in vitro* oxidative metabolites of the COX-2 selective inhibitor L-766,112
- P. Roy, Y. Leblanc, R. G. Ball,
C. Bricdeau, C. C. Chan, N. Chauret,
W. Cromlish, D. Ethier,
J. Y. Gauthier, R. Gordon, G. Greig,
J. Guay, S. Kargman, C. K. Lau,
G. O'Neill, J. Silva, M. Thérien,
C. van Staden, E. Wong, L. Xu and
P. Prasit 57 A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-*b*][1,2,4]-triazoles
- S. Routier, J.-L. Bernier,
J.-P. Catteau and C. Bailly 63 Highly preferential cleavage of unpaired guanines in DNA by a functionalized salen-nickel complex
- T. A. Lyle, Z. Chen, S. D. Appleby,
R. M. Freidinger, S. J. Gardell,
S. D. Lewis, Y. Li, E. A. Lyle,
J. J. Lynch, Jr, A. M. Mulichak,
A. S. Ng, A. M. Naylor-Olsen and
W. M. Sanders 67 Synthesis, evaluation, and crystallographic analysis of L-371,912: a potent and selective active-site thrombin inhibitor
- A. H. Krotz, P. Klopchin, D. L. Cole
and V. T. Ravikumar 73 Phosphorothioate oligonucleotides: largely reduced (*n*-1)-mer and phosphodiester content through the use of dimeric phosphoramidite synthons
- C. Dominguez, D. J. Carini,
P. C. Weber, R. M. Knabb,
R. S. Alexander, C. A. Kettner and
R. R. Wexler 79 S₁ heterocyclic thrombin inhibitors
- K. Sasaki, N. Minowa, H. Kuzuhara,
S. Nishiyama and S. Omoto 85 Synthesis and hepatoprotective effects of soyasapogenol B derivatives
- D. J. Hlasta, D. C. Bode, J. J. Court,
R. C. Desai, E. D. Pagani and
P. J. Silver 89 Imidazotriazinone inhibitors of the Ca²⁺-calmodulin sensitive phosphodiesterase (PDE I)
- Z. Yu and Y.-H. Chu 95 Combinatorial epitope search: pitfalls of library design
I Instructions to Contributors
V Aims & Scope



PII: S0960-894X(96)00584-7

S₁ HETEROCYCLIC THROMBIN INHIBITORSC. Dominguez,* D. J. Carini, P.C. Weber,¹ R. M. Knabb,
R. S. Alexander, C. A. Kettner, and R. R. Wexler.*DuPont Merck Pharmaceutical Company, Experimental Station,
P.O. Box 80500, Wilmington, DE 19880-0500.*

Abstract: A series of boropeptides have previously been described by Kettner et al. to be potent thrombin inhibitors. DuP 714 is a representative of this class of compounds with a $K_i = 0.040$ nM, but this inhibitor has undesirable side effects. New and selective boronic acid thrombin inhibitors have been developed by replacing the guanidine of the boroarginine side chain with various heterocycles ranging in size and basicity.

Copyright © 1996 Elsevier Science Ltd

Thrombin is involved in the pathogenesis of thrombosis. It functions as the last protease in the blood coagulation cascade hydrolyzing fibrinogen to insoluble fibrin.² Boropeptides are highly effective inhibitors of thrombin.³ DuP 714, Ac-(D)-Phe-Pro-boroArg-OH, is effective in preventing both venous and arterial thrombosis,² but it has a low margin of safety. DuP 714 has a K_i of 0.040 nM for thrombin and is two orders of magnitude less reactive with other plasma proteases. However, it readily inhibits trypsin and it is our expectation that compounds with greater selectivity will provide safer inhibitors.

X-ray crystal structures of thrombin and trypsin revealed that the thrombin P₁ pocket is slightly larger than that of trypsin. The Ser¹⁹¹ in trypsin narrows the P₁ pocket (Figure 1). We envisioned utilizing the pocket size differences between thrombin and trypsin to obtain selectivity over trypsin and other relevant serine proteases. We also wanted to explore the possibility of decreasing the basicity of the guanidine group of DuP 714 with various heterocycles as the literature suggests that increased toxicity may be attributed to highly basic functionalities.⁴ Herein, we report selective 5- and 6-membered heterocycles ranging in size and basicity, and the identification of the butanesulfonamide as a potent replacement of the acetamide group in DuP 714.


DuP 714

Figure 1. Superimposition of the S₁ Pockets of Thrombin and Trypsin.






Figure 2. Co-crystal structure of Compound 1 in Thrombin.



Replacing the guanidine group of DuP 714 with a heterocycle provided selectivity over trypsin and FXa (Table 1, compound 2). However we lost inhibitory potency against thrombin compared to DuP 714. We also

observed that the butanesulfonamide derivative **2** greatly increased the inhibitory affinity for thrombin compared to the acetyl derivative **1**. Modeling of derivative **2** in the thrombin active site suggests that the increase in affinity is due to the longer bond length of the sulfonamide bond which allows one of the sulfonamide oxygens to form a H-bond with the NH of Gly²¹⁸.

Table 1. S₁ 6-Membered Heterocyclic Thrombin Inhibitors



No	R ₂	R ₁	Thrombin	Trypsin	FXa*
1		Ac	43	>1200	>6000
2		SO ₂ Bu	2.1	214	>6000
3		Ac	150	ND	ND
4		Ac	230	>1200	>6000
5		Ac	2000	>1200	ND
6		Ac	600	>1200	>6000
7		SO ₂ Bu	8.8	ND	ND


ND = Not determined. The K_i's were determined as described by Kettner et al.^{3a}

*FXa is another serine protease involved in the coagulation cascade.^{3b}

Co-crystallization of compound **1** in thrombin also revealed that the pyrimidine ring was only in the P₁ specificity pocket 50% of the time (Figure 2) and yet we obtained nanomolar K_i affinity for thrombin.⁵ The X-ray structure of **1** may explain why the thiol analog **5** was not as potent as aminopyrimidine **6**. The loss in potency of compound **5** is probably due to the longer sulfur bond in the thiopyrimidine, which may not be accommodated in the P₁ specificity pocket. Pyrimidine **7** clearly exemplifies how vital the butanesulfonamide

group is to increasing thrombin inhibition compared to acetamide group in compound **5**. Interestingly, 2-aminopyrimidine **3** lost 2.5-fold affinity for thrombin compared to compound **1** and the pyridine derivative **4** also lost affinity for thrombin compared to **3**, suggesting that the chlorine atom of compound **1** and the 2-amino group of compound **1** and **3** must play a role in the binding.

Table 2. S₁ 5-Membered Heterocyclic Thrombin Inhibitors



No.	R ₂	R ₁	Thrombin	Trypsin	FXa
8		Ac	1.7	20	>6000
9		SO ₂ Bu	3.2	40	970
10		SO ₂ Bu	15	>1200	6000
11		Ac	650	>1200	>6000
12		Ac	67	27	6000
13		Ac	199	>1200	>6000
14		Ac	507	>1200	>6000
15		Ac	350	>1200	6000

Table 2 illustrates representative examples of the 5-membered S₁ heterocyclic thrombin inhibitors. The 2-aminoimidazole analogs proved to be the most potent of this series even though X-ray results suggest that the amino group does not interact with Asp¹⁸⁹. These compounds demonstrate that we were indeed able to obtain potent and selective thrombin inhibitors with a less basic P₁ group.

The 2-nitroimidazole analog **10** (Table 2) also exhibited good affinity for thrombin and excellent selectivity over trypsin and FXa. Here again the butanesulfonamide group greatly increased the affinity for thrombin compared to the acetamide group (**11**). The nitro group probably plays a key role in the selectivity over trypsin due the size of the 2-nitroimidazole versus the smaller size of the S₁ pocket of trypsin. This is in contrast to the smaller imidazole compound (**12**), which shows no selectivity over trypsin.


The more acidic heterocycles, such as the triazoles (**13** and **14**), and the tetrazole (**15**) did not exhibit the same affinity for thrombin as the imidazole analogs. Presumably the more basic the P₁ group, the stronger the interaction with Asp¹⁸⁹ in the specificity pocket of thrombin.

Chemistry

All the guanidine replacements were prepared from the α -aminoboronic acid **16**, which is obtained via Matteson chemistry.^{3,6} Peptide coupling with isobutylchloroformate (IBCF), N-methylmorpholine (NMM), and triethylamine in THF at 0 °C gave intermediate **17**. Compounds **5**, **6**, and **8-15** were prepared via alkylation of intermediate **17** with the appropriate heterocycles.⁷

The 2-aminopyrimidin-6-yl compounds were prepared via the ornithine intermediate by azide formation followed by catalytic hydrogenation and chlorine displacement.

Synthesis



Reagents: (a) IBCF, NMM, R₁(D)Phe-Pro-OH, Et₃N, 0 °C, 85%; (b) NaN₃, DMF, 80%; (c) H₂, Pd(OH)₂/C, HCl; 90% (d) Et₃N, DMF, R₂-Cl, 60 °C, 50-60%; (e) R₂-H, DMF, K₂CO₃, 60 °C, 60%.

Conclusion

By manipulating the size and basicity of guanidine replacements potent and selective thrombin inhibitors (**2**, **8**, and **9**) have been obtained. Additionally the N-butanefulfonamide group has been identified as a potent replacement for the N-acetyl group of DuP 714. Although the affinity of these compounds is decreased compared to DuP 714, they are more selective for thrombin over other serine proteases.

Acknowledgements

We wish to thank J. M. Luetgen, L. J. Mersinger, and S. Spitz for obtaining compound binding data.

References and Notes

1. Current address: Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, N.J. 07033.
2. Knabb, R. M.; Kettner, C. A.; Timmermans, P. B. W. M.; Reilly, T. M. *Thromb. Haemostasis* **1992**, *67*, 56.
3. (a) Kettner, C. A.; Mersinger, L.; Knabb, R. *J. Biol. Chem.* **1990**, *265*, 18289. (b) Radcliffe, R.; Nemerson, Y. In *Methods in Enzymology*; Lorand, L., Ed; Academic: London, 1976, Vol XLV, p 49.
4. (a) Okamoto, S.; Hijikata, A. *Biochim. Biophys. Res. Commun.* **1981**, *101*, 440. (b) Hijikata-Okunomiya, A.; Okamoto, S. *Thromb. Haemostasis* **1992**, *18*, 135. (c) Angliker, H.; Wilstrom, P.; Shaw, E. *Biochim J.* **1990**, *266*, 829. (d) Elgendy, S.; Deadman, J.; Patel, G.; Green, D.; Chino, N.; Goodwin, C. A.; Scully, M. F.; Kakkar, V. V.; Claeson, G. *Tetrahedron Lett.* **1992**, *33*, 4209. (e) Misra, R. N.; Kelly, Y. K.; Brown, B. R.; Roberts, D. G. G. M.; Chong, S.; Seiler, S. M. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2165.
5. Data were refined to 2.3 Å resolution and the structure refined to an R_{factor} 0.211.
6. Matteson, D. S.; Jeshi, P. K.; Sadha, K. M. *Organometallics* **1984**, *3*, 1284.
7. Satisfactory spectral data were obtained for all new compounds.

(Received in USA 31 October 1996; accepted 25 November 1996)